Wistar study proposes hypothesis of how Epstein-Barr virus infects host

Wistar scientists uncover new viral mechanism for evading immunity, identifying a new drug target

Researchers at The Wistar Institute have identified a previously unknown mechanism by which viruses can reprogram mitochondrial structure to silence immune responses and ensure successful viral reproduction.

May 23, 2025

Vol.51 No.20

In Brief

Wistar receives $600,000 grant to expand apprenticeship programs

The Wistar Institute’s Hubert J.P. Schoemaker Education and Training Center is expanding its apprenticeship programs and bolstering job opportunities in the life science sector based on a recent $600,000 PASmart Grant from the Pennsylvania Department of Labor & Industry.

February 07, 2025

Vol.51 No.05

Clinical Roundup

Urine test for prostate cancer could be used at home, study finds

Researchers at Vanderbilt and the University of Michigan have shown that an at-home urine test for prostate cancer screening is highly accurate.

February 07, 2025

Vol.51 No.05

Conversation with The Cancer Letter

After 25 years as FDA’s chief cancer strategist, Richard Pazdur reflects on opportunities for change at the agency

In 1999, Richard Pazdur, a GI oncologist at MD Anderson, saw an FDA recruitment ad in The New England Journal of Medicine. The agency was looking for a director of the FDA Division of Oncology Drug Products.

Rybrevant + Lazcluze show improvement in OS versus osimertinib

Johnson & Johnson announced positive topline results for overall survival from the phase III MARIPOSA study, evaluating Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) as a first-line therapy for patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions (ex19del) or L858R substitution mutations.

January 10, 2025

Vol.51 No.01

Drugs & Targets

FDA clears IND application for Recursion’s LSD1 inhibitor REC-4539

FDA cleared an investigational new drug application for a phase I/II clinical trial of REC-4539, a brain penetrant LSD1 inhibitor. Initial clinical investigation will focus on small cell lung cancer while also exploring several other solid tumor indications.

January 10, 2025

Vol.51 No.01

Wistar study proposes hypothesis of how Epstein-Barr virus infects host

YOU MAY BE INTERESTED IN

Wistar scientists uncover new viral mechanism for evading immunity, identifying a new drug target

Wistar receives $600,000 grant to expand apprenticeship programs

Urine test for prostate cancer could be used at home, study finds

After 25 years as FDA’s chief cancer strategist, Richard Pazdur reflects on opportunities for change at the agency

Rybrevant + Lazcluze show improvement in OS versus osimertinib

FDA clears IND application for Recursion’s LSD1 inhibitor REC-4539

Renew today!

Subscriber content

Never miss an issue!

Login